致：香港交易及結算所有限公司 公司名稱: 中國生命集團有限公司 呈交日期: 2026年4月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08296 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | | 1 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | | 1 HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HKD 1,000,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月 ...

Financial Performance - The total revenue for the year ended December 31, 2025, was RMB 64,380,000, a decrease of 13.6% compared to RMB 74,542,000 in 2024[4] - The gross profit for the same period was RMB 30,950,000, down from RMB 33,212,000, reflecting a gross margin decline[4] - The operating loss from continuing operations increased to RMB 7,555,000, compared to RMB 3,348,000 in the previous year[4] - The net loss attributable to the owners of the company for the year was RMB 6,564,000, compared to RMB 8,699,000 in 2024, indicating a reduction in losses[6] - The basic and diluted loss per share from continuing operations was RMB (6.89) for 2025, slightly improved from RMB (7.16) in 2024[7] - The total comprehensive loss for the year was RMB 5,554,000, compared to RMB 9,645,000 in the previous year, showing an improvement[5] - The company experienced a net loss of RMB 8,671,000 before tax for 2025, compared to a loss of RMB 7,454,000 in 2024, indicating ongoing financial challenges[25] - For the fiscal year 2025, the company reported a pre-tax loss of RMB 6,564,000, compared to a loss of RMB 8,699,000 in 2024, indicating an improvement of approximately 24.5% year-over-year[35] Revenue Breakdown - The revenue from funeral services in other regions (China, Hong Kong, and Taiwan) was RMB 63,762,000, while the revenue from Vietnam's funeral services was RMB 616,000, indicating a significant reliance on the other regions for revenue generation[23][27] - The total revenue from the Chinese market was RMB 62,415,000 in 2025, down from RMB 67,035,000 in 2024, reflecting a decrease of approximately 6.4%[27] - The revenue from Taiwan decreased to RMB 1,220,000 in 2025 from RMB 2,188,000 in 2024, showing a decline of approximately 44.3%[27] - Revenue from the Hong Kong business decreased by approximately 86.0%, falling to around RMB 745,000 from RMB 5,319,000, largely due to the completion of a major delivery of biotechnology instruments in the previous year[53] - The revenue from biotechnology and other businesses was RMB 618,000 in 2025, a slight increase from RMB 4,500,000 in 2024, indicating a shift in focus towards this segment[23][24] Operational Costs - Administrative expenses rose to RMB 37,984,000 from RMB 34,716,000, indicating increased operational costs[4] - The total cost of inventory recognized as an expense for 2025 was RMB 9,290,000, compared to RMB 12,935,000 in 2024, showing a significant decrease of approximately 28.5%[29][30] - The total depreciation and amortization expenses for 2025 amounted to RMB 6,713,000, a decrease from RMB 7,226,000 in 2024, reflecting a reduction of about 7.1%[29][30] - The company reported a total of RMB 1,067,000 in interest expenses for 2025, a slight decrease from RMB 1,473,000 in 2024, reflecting a reduction of about 27.5%[28] - The company incurred a total income tax expense of RMB 2,948,000 for 2025, down from RMB 2,817,000 in 2024, which represents an increase of approximately 4.6%[31] Asset and Liability Management - Non-current assets decreased from RMB 54,248 thousand in 2024 to RMB 46,494 thousand in 2025, a decline of approximately 14%[8] - Current assets decreased from RMB 196,378 thousand in 2024 to RMB 182,934 thousand in 2025, a decline of about 7%[8] - Total liabilities decreased from RMB 133,611 thousand in 2024 to RMB 128,392 thousand in 2025, a reduction of approximately 4%[9] - Net current assets decreased from RMB 62,767 thousand in 2024 to RMB 54,542 thousand in 2025, a decline of around 13%[8] - Total equity decreased from RMB 103,534 thousand in 2024 to RMB 98,195 thousand in 2025, a decrease of about 5%[9] Strategic Focus and Future Plans - The company plans to continue focusing on cost management and operational efficiency to improve future performance[3] - The company aims to diversify its business model to ensure sustainable growth by expanding into the "low-altitude economy" and life sciences sectors[53] - The company is actively deploying resources in strategic emerging industries to ensure sustainable growth and has transitioned from a traditional funeral service provider to a high-tech enterprise with independent R&D capabilities[48] - The company has established a non-wholly owned subsidiary, Bat Shark Future (Guangdong) Aviation Technology Co., Ltd., to lead the development of new energy unmanned ground effect vehicles, achieving a significant milestone with the successful first flight test of its first-generation aircraft FU1[48] - The company is focusing on accelerating the commercialization process of new products and enhancing collaboration with industry partners to maximize shareholder returns[49] Discontinued Operations - The company has ceased operations related to the sale of cemetery and tombstone services in Vietnam, impacting comparative figures[11] - The company successfully completed the sale of its entire equity interest in Junqun Development Limited for a cash consideration of HKD 10,000,000, effectively terminating its operations in Vietnam[66] - Losses from discontinued operations in Vietnam narrowed from approximately RMB 2,648,000 in the previous year to about RMB 61,000 this year, demonstrating the effectiveness of the strategic shift[66] - The revenue from discontinued operations for the period from January 1 to August 15, 2025, is RMB 616,000, compared to RMB 401,000 for the entire year of 2024, marking a 53.7% increase[43] - The operating loss from discontinued operations for the period is RMB (445,000), a significant improvement from RMB (2,633,000) in 2024, indicating an 83.1% reduction in losses[43] Corporate Governance and Compliance - The company has complied with the corporate governance code based on the GEM listing rules, with a focus on high-quality board and transparency to shareholders[109] - No significant violations of applicable laws and regulations have occurred during the year[111] - The audit committee, consisting of three independent non-executive directors, has reviewed the audited consolidated financial statements and confirmed compliance with applicable accounting standards[114] Investment and Financial Management - The group maintained a cautious financial management strategy and did not utilize any financial instruments for hedging purposes during the year[72] - The group is actively monitoring economic conditions and acknowledges potential changes that may impact financial performance[73] - The group has established a strategic partnership with a professional investment firm specializing in venture capital and emerging industry consulting to enhance asset identification and management capabilities[77] - The group’s current bank borrowings were approximately RMB 992,000, with non-current borrowings at RMB 143,000 and RMB 240,000 respectively[70] - The net debt-to-equity ratio remains prudent at approximately 57.2% as of December 31, 2025, down from 58.7% in 2024, ensuring financial flexibility for strategic investment opportunities[82]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因本公佈全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失 承 擔 任 何 責 任。 （股份代號：8296） （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） 董事會會議通告 中 國 生 命 集 團 有 限 公 司（「本公司」）之 董 事（「董 事」）會（「董事會」）謹 此 宣 佈， 董 事 會 會 議 將 於 二 零 二 六 年 三 月 三 十 一 日（星 期 二）舉 行，以 便 處 理 下 列 事 項： 承董事會命 中國生命集團有限公司 主席兼執行董事 許建春 香 港，二 零 二 六 年 三 月 十 三 日 – 1 – 1) 省覽及通過本公司及其附屬公司截至二零二五年十二月三十一日止 年 度 之 經 審 核 綜 合 財 務 報 表（「經審核年度業績」）； 2) 通過將經審核年度業績公告稿本及通過經審核年度業績公告刊登於 香 港 聯 合 交 易 所 有 限 公 司 之 網 站 及 本 公 司 網 站； 3) ...

公司名稱: 中國生命集團有限公司 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08296 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 1 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 1 | HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HKD 1,000,000,000 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2 ...

呈交日期: 2026年2月2日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國生命集團有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08296 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 1 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 1 | HKD | | 1,000,000,000 | 本月底法定/註冊股本 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國生命集團有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 第 2 頁 共 10 頁 v 1.1.1 III.已發行股份及/或庫存股份變動詳情 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08296 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 1 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國生命集團有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08296 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | | 1 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | | 1 HKD | | 1,000,000,000 | 本月底法定/註冊 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 公司名稱: 中國生命集團有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08296 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 1 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 1 | HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HKD 1,000,000,000 FF301 截至月份: 2025年 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國生命集團有限公司 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08296 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 1 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 1 | HKD | | 1,000,000,000 | 本月底法定/註冊股 ...

Core Viewpoint - China Life Group (08296.HK) announced the appointment of Zhu Bing as a non-executive director, effective from September 16, 2025 [1] Company Summary - Zhu Bing has been appointed as a non-executive director of China Life Group [1]